Why is research on herbal medicinal products important and how can we improve its quality?

Journal of Traditional and Complementary Medicine

Volumn 4, Issue 1, 2014, Pages 1-7

  Pelkonen, Olavi ^a   Xu, Qihe ^b   Fan, Tai Ping ^c  

^a UNIVERSITY OF OULU   (Finland)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Herbal medicinal products; Network pharmacology; Omic tools; Polypharmacology; Traditional chinese herbal medicines

Indexed keywords

EID: 84894521193     PISSN: None     EISSN: 22254110     Source Type: Journal    
DOI: 10.4103/2225-4110.124323     Document Type: Article

References (78)

1. Salimifar M, Fatehi-Hassanabad Z, Fatehi M. A Review on natural products for controlling Type 2 diabetes with an emphasis on their mechanisms of actions. Curr Diabetes Rev 2013;9:402-11.
2. Jiao C, Xie YZ, Yang X, Li H, Li XM, Pan HH, et al. Anticancer Activity of Amauroderma rude. PLoS One 2013;8:e66504.
3. Williamson EM, Lorenc A, Booker A, Robinson N. The rise of traditional Chinese medicine and its materia medica: A comparison of frequency and safety of materials and species used in Europe and China. J Ethnopharmacol 2013;149:453-62.
4. Xu J, Liu M, Xia Z. Will the Europe Union's Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC) be against traditional Chinese medicine in EU market? J Evid Based Med 2013;6:104-8.
5. Ning Z, Lu C, Zhang Y, Zhao S, Liu B, Xu X, et al. Application of plant metabonomics in quality assessment for large-scale production of traditional Chinese medicine. Planta Med 2013;79:897-908.
6. Kosalec I, Kopjar N, Kremer D. Antimicrobial activity of willowherb (Epilobium angustifolium L.) leaves and flowers. Curr Drug Targets 2013;14:986-91.
7. Bell IR, Schwartz GE, Boyer NN, Koithan M, Brooks AJ. Advances in integrative nanomedicine for improving infectious disease treatment in public health. Eur J Integr Med 2013;5:126-40.
8. Xi S, Qian L, Tong H, Yue L, Zhao H, Wang D, et al. Toxicity and clinical reasonable application of Taoren (Semen Persicae) based on ancient and modern literature research. J Tradit Chin Med 2013;33:272-9.
9. He S. Chinese herbal dose in ancient and modern times: A comparative study. J Tradit Chin Med 2013;33:268-71.
10. Su K, Zhu F, Guo L, Zhu Y, Li W, Xiong X. Retrospective study on Professor Zhongying Zhou's experience in Traditional Chinese Medicine treatment on diabetic nephropathy. J Tradit Chin Med 2013;33:262-7.
11. Lei HP, Ji W, Lin J, Chen H, Tan ZR, Hu DL, et al. Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol 2009;68:201-6.
12. Qiu F, Wang G, Zhang R, Sun J, Jiang J, Ma Y. Effect of danshen extract on the activity of CYP3A4 in healthy volunteers. Br J Clin Pharmacol 2010;69:656-62.
13. Armstrong NC, Ernst E. The treatment of eczema with Chinese herbs: A systematic review of randomized clinical trials. Br J Clin Pharmacol 1999;48:262-4.
14. Jang DJ, Lee MS, Shin BC, Lee YC, Ernst E. Red ginseng for treating erectile dysfunction: A systematic review. Br J Clin Pharmacol 2008;66:444-50.
15. Barnes J. Quality, efficacy and safety of complementary medicines: Fashions, facts and the future. Part I. Regulation and quality. Br J Clin Pharmacol 2003;55:226-33.
16. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John's wort extracts on CYP3A: A systematic review of prospective clinical trials. Br J Clin Pharmacol 2006;62:512-26.
17. Posadzki P, Watson L, Ernst E. Herb-drug interactions: An overview of systematic reviews. Br J Clin Pharmacol 2013;75:603-18.
18. Teschke R, Frenzel C, Glass X, Schulze J, Eickhoff A. Herbal hepatotoxicity: A critical review. Br J Clin Pharmacol 2013;75:630-6.
19. Nutraceuticals World. International Perspectives on Herbs and Botanicals. Where are the opportunities for growth and what challenges stand in the way of long-term market success? (By Julie Dennis, Contributing Writer): Available from: http://www.nutraceuticalsworld.com/issues/2013-07/view-features/ international-perspectives-on-herbs-botanicals/[Last accessed on 2012 Nov 25].
20. De Vos P. European materia medica in historical texts: Longevity of a tradition and implications for future use. J Ethnopharmacol 2010;132:28-34.
21. Market Research. Report of Traditional Chinese Medicine Industry under, 2009. China Research and Intelligence Co., Ltd. April 7, 2009, 60 Pages-SKU: CRIC2207445. In: Available from: http://www. marketresearch.com/China-Research- and-Intelligence-Co-Ltd-v3627/Traditional-Chinese-Medicine?2207445/[Last accessed on 2013 Nov 25].
22. Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 2008;105:4826-31.
23. Kuhn T, Wang Y. Artemisinin-an innovative cornerstone for anti-malaria therapy. Prog Drug Res 2008;66:383-422.
24. VEREGEN (sinecatechins) ointment. Available from: http://dailymed. nlm.nih.gov/dailymed/lookup.cfm-setid=2c1cd745-79ab-487d-b759-9 95794cedb92 [Last accessed on 2013 Nov 25].
25. Chen ST, Dou J, Temple R, Agarwal R, Wu KM, Walker S. New therapies from old medicines. Nat Biotechnol 2008;26:1077-83.
26. Fan TP, Deal G, Koo HL, Rees D, Sun H, Chen S, et al. Future development of global regulations of Chinese herbal products. J Ethnopharmacol 2012;140:568-86.
27. Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, et al. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res 2009;29:4083-92.
28. Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (CAESA). Available from: http://clinicaltrials.gov/show/ NCT01659580 [Last accessed on 2013 Nov 25].
29. Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, et al. Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis B. Zhong Xi Yi Jie He Xue Bao 2003;1:89-98.
30. Hu YY, Liu P, Liu C. Investigation on indication of fuzheng huayu capsule against hepatic fibrosis and its non-invasive efficacy evaluation parameters: Data analysis of liver biopsy of 50 patients with chronic hepatitis B before and after treatment. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006;26:18-22.
31. Phase II Trial to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis. Available from: http://clinicaltrials.gov/ct2/show/NCT00854087-term=Fuzheng+Huayu and rank=1 [Last accessed on 2013 Nov 25].
32. The US Department of Health and Human Services, National Institutes of Health, The National Center for Complementary and Alternative Medicine (NCCAM). Available from: http://nccam.nih.gov/about [Last accessed on 2013 Nov 25].
33. Pfizer grows R and D work in China. Available from: http://www. chinadaily.com.cn/business/2009-08/10/content-8548101.htm [Last accessed on 2013 Nov 25].
34. GSK to develop traditional Chinese medicine. Available from: http://www.chinadaily.com.cn/business/2012-09/07/content-15743913. htm [Last accessed on 2013 Nov 25].
35. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 2009;461:218-23.
36. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: A network-based approach to human disease. Nat Rev Genet 2011;12:56-68.
37. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006;16:127-36.
38. Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 2008;4:682-90.
39. Normile D. Asian medicine. The new face of traditional Chinese medicine. Science 2003;299:188-90.
40. Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: Triumphs and trials. Cell 2007;130:769-74.
41. van der Greef J, McBurney RN. Rescuing drug discovery: In-vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 2005;4:961-7.
42. van Wietmarschen H, Yuan K, Lu C, Gao P, Wang J, Xiao C, et al. Systems biology guided by Chinese medicine reveals new markers for sub-typing rheumatoid arthritis patients. J Clin Rheumatol 2009;15:330-7.
43. The Quantitative and Systems Pharmacology Working Group of the US National Institutes of Health. White Paper on Quantitative and Systems Pharmacology in the Post-Genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms. Available from: http://www.nigms.nih.gov/ nr/rdonlyres/8ecb1f7c-be3b-431f-89e6-a4341 1811ab1/0/systemspharmawpsorger2011. pdf [Last accessed in 2011 Oct].
44. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol 2006;24:805-15.
45. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecular targets for known drugs. Nature 2009;462:175-81.
46. Keiser MJ, Irwin JJ, Shoichet BK. The chemical basis of pharmacology. Biochemistry 2010;49:10267-76.
47. Xu Q, Qu F, Pelkonen O. Network Pharmacology and Traditional Chinese Medicine. In: Sakagami H, editor. Alternative Medicine. Rijeka, Croatia: Intech; 2012. p. 277-97.
48. Gilmore JM, Washburn MP. Advances in shotgun proteomics and the analysis of membrane proteomes. J Proteomics 2010;73:2078-91.
49. Doerr A. Targeted proteomics. Nat Methods 2011;8:43.
50. Yan W, Luo J, Robinson M, Eng J, Aebersold R, Ranish J. Index-ion triggered MS2 Ion quantification: A novel proteomics approach for reproducible detection and quantification of targeted proteins in complex mixtures. Mol Cell Proteomics 2011;10:M110.005611.
51. Engmann O, Campbell J, Ward M, Giese KP, Thompson AJ. Comparison of a protein-level and peptide-level labeling strategy for quantitative proteomics of synaptosomes using isobaric tags. J Proteome Res 2010;9:2725-33.
52. Fukushima A, Kusano M, Redestig H, Arita M, Saito K. Integrated omics approaches in plant systems biology. Curr Opin Chem Biol 2009;13:532-8.
53. Simon Z, Peragovics A, Vigh-Smeller M, Csukly G, Tombor L, Yang Z, et al. Drug effect prediction by polypharmacology-based interaction profiling. J Chem Inf Model 2012;52:134-45.
54. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011;10:507-19.
55. Pelkonen O, Pasanen M, Lindon JC, Chan K, Zhao L, Deal G, et al. Omics and its potential impact on R and D and regulation of complex herbal products. J Ethnopharmacol 2012;140:587-93.
56. Uzuner H, Fan TP, Dias A, Guo DA, El-Nezami HS, Xu Q. Establishing an EU-China consortium on traditional Chinese medicine research. Chin Med 2010;5:42.
57. Journal of Ethnopharmacology Special Issue; 2012: Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era. Vol. 140. In: Xu Q, Bauer R, editors. Available from: http://www. sciencedirect.com/science/ journal/03788741/140 [Last accessed on 2013 Nov 25].
58. Uzuner H, Bauer R, Fan TP, Guo DA, Dias A, El-Nezami H, et al. Traditional Chinese medicine research in the post-genomic era: Good practice, priorities, challenges and opportunities. J Ethnopharmacol 2012;140:458-68.
59. Tilton R, Paiva AA, Guan JQ, Marathe R, Jiang Z, van Eyndhoven W, et al. A comprehensive platform for quality control of botanical drugs: A case study of Huangqin Tang and PHY906. Chin Med 2010;5:30.
60. Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med 2010;2:45ra59.
61. The GP-TCM Research Association. Available from: http://www.gp-tcm. org. [Last accessed on 2013 Nov 25].
62. Hu Q, Noor M, Wong YF, Hylands P, Simmonds MS, Xu Q, et al. In vitro anti-fibrotic activities of herbal compounds and herbs. Nephrol Dial Transplant 2009;24:3033-41.
63. Wong YF, Qu S, Kong Q, Zhang XL, Liang XM, Hu Q, et al. Knowledge-based discovery of anti-fibrotic and pro-fibrotic activities from Chinese materia medica. In: Kuang X, editor. Recent Advances in Theories and Practice of Chinese Medicine. Rijeka, Croatia: Intech; 2012. p. 337-52.
64. Sengupta S, Toh SA, Sellers LA, Skepper JN, Koolwijk P, Leung HW, et al. Modulating angiogenesis: The Yin and the Yang in Ginseng. Circulation 2004;110:1219-25.
65. Fan TP, Yeh JC, Leung KW, Yue PY, Wong RN. Angiogenesis: From plants to blood vessels. Trends Pharmacol Sci 2006;27:297-309.
66. Leung KW, Cheng YK, Mak NK, Chan KK, Fan TP, Wong RN. Signaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells. FEBS Lett 2006;580:3211-6.
67. Leung KW, Pon YL, Wong RN, Wong AS. Ginsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related phosphatidylinositol 3-kinase/Akt and beta-catenin/T-cell factor-dependent pathway in human endothelial cells. J Biol Chem 2006;281:36280-8.
68. Leung KW, Cheung LW, Pon YL, Wong RN, Mak NK, Fan TP, et al. Ginsenoside-Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through estrogen receptor beta. Br J Pharmacol 2007;152:207-15.
69. Jin J, Shahi S, Kang HK, van Veen H, Fan TP. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 2006;345:1308-14.
70. Yeh JC, Cindrova-Davies T, Belleri M, Morbidelli L, Miller N, Cho CW, et al. The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis 2011;14:187-97.
71. Yeh JC, Garrard IJ, Cho CW, Bligh SW, Lu GH, Fan TP, et al. Bioactivity-guided fractionation of the volatile oil of Radix Angelica sinensis designed to preserve the synergistic effects of the mixture followed by identification of the active principles. J Chromatogr A 2012;1236:132-8.
72. Lam HW, Lin HC, Lao SC, Gao JL, Hong SJ, Leong CW, et al. The angiogenic effects of Angelica sinensis extract on HUVEC in vitro and zebrafish in vivo. J Cell Biochem 2008;103:195-211.
73. Mohd Fauzi F, Koutsoukas A, Lowe R, Joshi K, Fan TP, Glen RC, et al. Chemogenomics approaches to rationalizing the mode-of-action of traditional chinese and ayurvedic medicines. J Chem Inf Model 2013. [Epub ahead of print].
74. Ouedraogo M, Baudoux B, Stévigny C, Nortier J, Colet JM, Efferth T, et al. Review of current and "omics" methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines and mushrooms. J Ethnopharmacol 2012;140:492-512.
75. Sevior DK, Hokkanen J, Tolonen A, Abass K, Tursas L, Pelkonen O, et al. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica 2010;40:245-54.
76. Hokkanen J, Tolonen A, Mattila S, Turpeinen M. Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci 2011;42:273-84.
77. Sevior DK. PhD Thesis, Complementary Products and Drug Interactions. Screening for the potential to cause pharmacokinetic interactions. RMIT-University, Melbourne, Australia, June 2012. 330 pp.
78. Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, Lewith G. Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol 2012;140:550-4.